Chosa (XSAT: CHOSA)

Currency in SEK

Last close As at 26/05/2023

SEK1.30

−0.22 (−14.47%)

Market capitalisation

SEK94m

New client – content coming soon.

Latest Insights

View More

Healthcare

RhoVac — On the home straight

Healthcare

RhoVac — COVID-19 vaccines versus RV001

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Claus Frisenberg Pedersen

    CFO

  • Neil Goldsmith

    Chairman

  • Peter Buhl Jensen

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 8.1 8.1 (95.6)
Relative 10.4 9.5 (95.8)
52 week high/low SEK35.0/SEK0.5

Financials

RhoVac’s Phase IIb BRaVac trial has been fully enrolled since September 2021. According to the latest guidance, key results are expected in May or June 2022, which is the most significant catalyst of the investment case so far. The BRaVac trial is investigating RV001, a tissue-agnostic cancer immunotherapy now known as onilcamotide, in prostate cancer patients with localised disease who have relapsed after treatment with curative intent. There is a lack of treatment options in this stage and patients would typically be offered a ‘watchful waiting’ approach even though there already are signs of the cancer reappearing, so the unmet need is high. Our valuation has increased slightly to SEK1.71bn or SEK89.5/share (from SEK84.9/share previously) after rolling the model forward.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free